Document Detail

NF-M trans-activates the human DNA topoisomerase II alpha promoter independently of c-Myb in HL-60 cells.
MedLine Citation:
PMID:  9379678     Owner:  NLM     Status:  MEDLINE    
Identifying transcriptional regulators of DNA topoisomerase II alpha (topo II alpha) is essential to decipher the mechanisms underlying leukemia cell resistance to topo II-directed antitumor drugs. We have previously reported that the proto-oncogene transcription factor c-Myb transactivates the topo II alpha promoter in several hematopoietic cell lines. Currently, we investigate whether NF-M, a C/EBP beta family member, cooperates with c-Myb in activating topo II alpha transcription. Although NF-M is the most efficacious trans-activator of topo II alpha that we have examined (approximately 38-fold over basal), NF-M does not appear to be involved in the endogenous transcriptional regulation of topo II alpha. Interestingly, we report that the sodium butyrate-dependent induction of the topo II alpha promoter observed previously appears to be mediated by c-Myb, independent of NF-M.
T L Brandt; D J Kroll
Related Documents :
20414968 - Intron-1 rs3761548 is related to the defective transcription of foxp3 in psoriasis thro...
8226898 - The highest levels of purine catabolic enzymes in mice are present in the proximal smal...
23121078 - Phosphodiesterase-4 inhibition improves corticosteroid insensitivity in pulmonary endot...
18505338 - V-myb suppresses phorbol ester- and modifies retinoic acid-induced differentiation of h...
19811308 - The 12/15-lipoxygenase pathway promotes osteoclast development and differentiation.
21566998 - Increases of stromelysin messenger-rna expression in ras-transformed ref cells in-vivo.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Leukemia research     Volume:  21     ISSN:  0145-2126     ISO Abbreviation:  Leuk. Res.     Publication Date:  1997 Aug 
Date Detail:
Created Date:  1997-11-12     Completed Date:  1997-11-12     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  7706787     Medline TA:  Leuk Res     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  711-20     Citation Subset:  IM    
Department of Pharmaceutical Sciences, University of Colorado School of Pharmacy, Denver, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antigens, Neoplasm
CCAAT-Enhancer-Binding Proteins
COS Cells
DNA Topoisomerases, Type II / genetics*
DNA Topoisomerases, Type II, Eukaryotic*
DNA-Binding Proteins / pharmacology*
Dose-Response Relationship, Drug
HL-60 Cells
Hela Cells
Isoenzymes / genetics*
Nuclear Proteins / pharmacology*
Promoter Regions, Genetic
Transcription Factors
Transcriptional Activation*
Grant Support
Reg. No./Substance:
0/Antigens, Neoplasm; 0/CCAAT-Enhancer-Binding Proteins; 0/DNA-Binding Proteins; 0/Isoenzymes; 0/Nuclear Proteins; 0/Transcription Factors; EC 5.99.1.-/DNA Topoisomerases, Type II, Eukaryotic; EC Topoisomerases, Type II; EC topoisomerase II alpha
Comment In:
Leuk Res. 1997 Nov-Dec;21(11-12):1033-6   [PMID:  9444936 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Amplified c-MYC sequences localized by fluorescence in-situ hybridization on double minute chromosom...
Next Document:  Exon 5 mutations in the p53 gene in relapsed childhood acute lymphoblastic leukemia.